<DOC>
	<DOCNO>NCT03091192</DOCNO>
	<brief_summary>This study design patient diagnose MET-driven , unresectable locally advanced metastatic Papillary Renal Cell Carcinoma . The purpose study see investigational new anti-cancer medication , savolitinib , effective treat patient MET-driven PRCC , compare another medication frequently use treat disease call sunitinib , side effect might cause .</brief_summary>
	<brief_title>Savolitinib vs. Sunitinib MET-driven PRCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Histologically confirm Papillary Renal Cell Carcinoma , unresectable locally advanced metastatic measurable disease per RECIST 1.1 . 2 . Confirmation METdriven PRCC without cooccurring Fumarate Hydratase Von Hippel Lindau mutation tumour sample use sponsordesignated central laboratory validate MET Next Generational Sequencing assay 3 . Patients receive prior systemic therapy well receive prior systemic therapy PRCC . Patients receive prior therapy must disease progression within 6 month last dose previous systemic therapy 4 . Adequate haematological , renal ( creatinine &lt; 2xULN ) , cardiac liver function 5 . Karnofsky performance status ≥ 80 6 . Ability swallow oral medicine . 1 . Most recent cytotoxic chemotherapy , immunotherapy , chemoimmunotherapy , investigational agent &lt; 21 day date randomisation 5 halflives agent , whichever longer . Most recent noncytotoxic target therapy &lt; 14 day date randomisation . 2 . Prior treatment MET inhibitor ( e.g . foretinib , crizotinib , cabozantinib , onartuzumab previous savolitinib ) sunitinb . 3 . Treatment strong inducer inhibitor CYP3A4 strong inhibitor CYP1A2 , take within 2 week possible stop least 2 week date randomisation . 4 . History serious liver disease 5 . Serious active infection gastrointestinal disease 6 . Uncontrolled hypertension ( BP ≥150/95 mmHg despite medical therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Papillary Renal Cell Cancer</keyword>
	<keyword>AZD6094</keyword>
	<keyword>Savolitinib</keyword>
</DOC>